Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cytheris Publication in Blood Demonstrates CYT107 Reverses Lymphopenia

Published: Tuesday, February 05, 2013
Last Updated: Monday, February 04, 2013
Bookmark and Share
Data strongly supports development of CYT107 for treatment of PML in lymphopenic patients.

Cytheris SA has announced the publication of a paper demonstrating that Cytheris' CYT107, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7) can enhance immune T cell recovery after a T cell-depleted (TCD) allogeneic hematopoietic stem cell transplantation (allo-HSCT).

The study detailed in the paper demonstrated an increase in functional T cells, including viral-specific T cells that recognize CMV, and enhanced T cell receptor diversity. Additionally, there was no significant GVHD or other serious toxicity.

The paper by Drs. Perales and van den Brink has been pre-published in the on-line version of the journal Blood (http://www.ncbi.nlm.nih.gov/pubmed/23012326).

It details the phase I study performed in 12 patients undergoing TCD allo-HSCT. The paper is titled "Recombinant Human Interleukin-7 (CYT107) Promotes T Cell Recovery Following Allogeneic Stem Cell Transplantation."

"Lymphopenia post-HSCT is a serious problem leading to mortality and morbidity, notably from potentially life-threatening infections and relapse. Several of these infections are resistant to standard treatments or have no treatment at all," said Dr Miguel Perales, MD, Director, Adult Bone Marrow Transplantation Fellowship, Memorial Sloan-Kettering Cancer Center, New York.

Dr Perales continued, "CYT107 is the first agent to demonstrate the ability to reverse post-transplant lymphopenia without increasing risks. It may offer the possibility to restore the T-cell immune system to fight these serious and often fatal infections, and improve survival."

"These data confirm the potential seen in other studies for CYT107 to treat lymphopenia and lymphopenia driven diseases. PML, Cytheris lead indication for CY107, is a rare and devastating disease with one year mortality of 40-50 per cent that is caused by reactivation of latent JC virus in lymphopenic patients," said Therese Croughs, chief medical officer at Cytheris.

Croughs continued, "We have already gathered clinical data supporting the efficacy and safety of CYT107 in PML through several compassionate use treatments. These new data in TCD allo-HSCT patients are particularly interesting in the context of PML due to the virus-specific immune responses. They also open the future possibility of use of CYT107 to treat resistant viral infections, such as CMV, in post-transplant and other lymphopenic populations."

The study was a phase I trial of r-hIL-7 (CYT107) in recipients of TCD allo-HSCTs. Twelve patients were treated with escalating doses of CYT107 administered weekly for 3 weeks. At baseline, patients were profoundly lymphopenic.

CYT107 induced a doubling in CD4+ and CD8+ T cells. The main effect of IL-7 was an expansion of effector memory T cells, the predominant subset identified in Cytheris patients. There was no significant effect on CD4+CD25+FoxP3+ T cells, NK or B cells.

Importantly, there were not only quantitative increases in T cells after a short course of IL-7, but an increase in functional T cells, including viral-specific T cells that recognize CMV. Enhanced TCR diversity was also observed after treatment.

The study drug was well tolerated with only one patient developing acute skin GVHD. The results indicate that r-hIL-7 can enhance immune recovery after a TCD allo-HSCT without causing significant GVHD or other serious toxicity.

"The results announced today strongly support the Cytheris strategy to conduct a pivotal registration study of CYT017 in PML," said Damian Marron, chief executive officer at Cytheris. "PML affects around 4,000 people in the US and EU alone. Bringing a treatment to this population would not only save and change patients' lives but would also respond to the pharmaceutical industry's desire to develop breakthrough drugs for targeted indications."

PML is a severe demyelinating disease of the central nervous system caused by the JC virus. It occurs in many conditions leading to severe lymphopenia such as HIV infection, some cancers and organ transplantation treated with immunosuppressive therapies.

PML is a very rare disease, affecting around four out of a million individuals. There is currently no marketed drug for the treatment of this devastating condition.

Cytheris has obtained scientific advice for a pivotal phase IIb study protocol with CYT107 in HIV-related PML. Cytheris reached an agreement with the EMA on the key study endpoints. Cytheris will start this phase IIb study, intended to be the pivotal registration study, in early 2013.

Additionally, The European Commission has granted an orphan designation for Cytheris' CYT017, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7), for the treatment of Progressive Multifocal Leukoencephalopathy (PML).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cytheris Appoints Damian Marron as Chief Executive Officer
Damian was previously CEO at Trophos SA.
Thursday, June 14, 2012
Cytheris Announces Interim Results from ECLIPSE II Hepatitis C Multicenter Study
Data to be presented at The Liver Meeting®, the 62nd annual meeting of the AASLD in San Francisco, November 4-8, 2011.
Wednesday, November 16, 2011
Cytheris to Present Interim Data from ECLIPSE II Hepatitis C Multicenter Study
Data to be presented at AASLD in San Francisco, November 4-8, 2011.
Monday, October 31, 2011
Cytheris Announces Results of Phase IIa Study Indicating that Recombinant Interleukin-7 Expands CD4 T-Cells in HIV-1 Infected Patients
Data from INSPIRE 2 HIV study show that CYT107 administration can significantly expand CD4 and CD8 T-cells with lower expression of PD-1 while increasing the expression of gut homing molecules that may result in the restoration of the CD4 T-cell population of the gut mucosa.
Friday, March 04, 2011
Cytheris Announces Interim Results of Phase I Study of Recombinant Human Interleukin-7
CYT107 has shown to promote T-cell recovery following T-cell depleted allogeneic hematopoietic stem cell transplantation.
Wednesday, December 08, 2010
Initiation of ORVACS-Sponsored Phase II Clinical Study into Attack of the Viral Reservoir of HIV Patients
By combining an integrase inhibitor and a CCR5 inhibitor with IL-7 to target or induce activation of latently infected cells this study aims to investigate whether exhausting the HIV reservoir and ultimately obtaining virus eradication is feasible.
Wednesday, November 03, 2010
Cytheris Announces Initiation of ORVACS-Sponsored Phase II Clinical Study to Attack Viral Reservoir of HIV Patients
Study aims to investigate whether exhausting the HIV reservoir and ultimately obtaining virus eradication is feasible.
Friday, October 29, 2010
Cytheris Initiates INSPIRE 3, a Phase II Clinical Trial of CYT107 in Chronically Infected HIV Patients
Phase II clinical program will evaluate the effect of repeated cycles of the company’s investigative immune-modulator in the treatment of Immunological Non-Responders.
Friday, September 24, 2010
Cytheris Announces Publication of Preclinical Study in Journal of Immunology Showing Interleukin-7 Promotes T Cell Viability, Trafficking and Functionality While Improving Survival in Sepsis
Study indicates rhIL-7 blocks sepsis-induced depletion of CD4 and CD8 T cells, enhances lymphocyte recruitment and prevents sepsis-induced loss in immunity leading to improved survival.
Tuesday, March 16, 2010
Cytheris Initiates INSPIRE 2, a Phase II Clinical Trial of Recombinant Human Interleukin-7
Study is designed to explore the impact of CYT107 on HIV specific T cell responses.
Tuesday, January 19, 2010
Cytheris Announces Initiation of NIAID/NIH-Sponsored Phase I/IIa Clinical Trial of Interleukin-7
Study to focus on immunotherapy for treatment of idiopathic CD4 lymphocytopenia, a rare condition for which no treatment currently exists.
Thursday, October 29, 2009
Cytheris’ Study Shows Combination of Interleukin-7 with Viral Vaccine Boosts Immunity to Tumors
The ability of adjuvant IL-7 to antagonize inhibitory networks at the cellular and molecular level has major implications for immunotherapy in the treatment of tumors.
Wednesday, May 27, 2009
Cytheris Announces Publication of IL-7 Primate Study Showing Rapid and Massive T cell Homing to the Gut
Results suggest potential of IL-7 in stimulating the T-cell repopulation of the gut, which is inaccessible to HAART therapy and constitutes a potent viral reservoir.
Friday, May 15, 2009
Cytheris Announces Phase I Study of Interleukin-7 as Immunotherapy in Treatment of Immunodeficient Transplant Recipients
Clinical trial is designed to investigate use of IL-7 in treatment of patients who are vulnerable to a variety of bacterial, viral, and fungal infections.
Thursday, April 24, 2008
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
“Sixth Sense” May Be More Than Just A Feeling
The NIH Study shows that two young patients with a mutation in the PIEZ02 have problems with touch and proprioception, or body awareness.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!